Rheumatology 1999; 38: 1081-1087
© 1999 British Society for Rheumatology
Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis
Department of Rheumatology, University Hospital Groningen and
1 Northern Centre for Health Care Research, University of Groningen, The Netherlands
Correspondence to:
M. D. Posthumus, Department of Rheumatology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
Objective. To evaluate the significance of serum matrix metalloproteinase-3 (MMP-3) levels in relation to the development of radiological damage (X-ray damage) in early rheumatoid arthritis (RA).
Methods. Serum MMP-3 levels were measured in 46 healthy controls (CTRL), 19 osteoarthritis (OA) and 78 RA patients with joint symptoms for <1 yr at presentation (T0): 48 patients without and 30 with X-ray damage at T0. Serum MMP-3, measured by ELISA, and X-ray damage, scored according to Sharp's method, were assessed at 0, 6, 12 and 24 months.
Results. MMP-3 levels in CTRL and OA were low or undetectable with no differences between the groups (P=0.19). Levels in RA were higher than in CTRL (P<0.01). Initial MMP-3 levels in patients with X-ray damage at T0 (n=30) were higher than the levels in patients without any X-ray damage during follow-up (n=19) (P<0.01), but were not different from those in patients who developed X-ray damage during the study (n=29) (P=0.11). In the patients without X-ray damage at T0, there was a significant correlation between MMP-3 at T0 and the total X-ray damage after 6 months (r=0.34, P=0.02) and 12 months (r=0.32, P=0.03). This correlation was almost exclusively determined by joint space narrowing in the Sharp score.
Conclusion. The serum MMP-3 level seems to be an indicator for the development of radiological damage in patients with early RA and appears to be particularly indicative of cartilage degradation.
KEY WORDS: Serum matrix metalloproteinase-3, Early rheumatoid arthritis, Radiological damage
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. W. SYVERSEN, R. LANDEWE, D. van der HEIJDE, J. M. BATHON, M. BOERS, V. P. BYKERK, O. FITZGERALD, D. D. GLADMAN, P. GARNERO, P. GEUSENS, et al. Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers J Rheumatol, August 1, 2009; 36(8): 1769 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Green, A. K. S. Gough, J. Devlin, J. Smith, P. Astin, D. Taylor, and P. Emery Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology, January 1, 2003; 42(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Catrina, J. Lampa, S. Ernestam, E. af Klint, J. Bratt, L. Klareskog, and A.-K. Ulfgren Anti-tumour necrosis factor (TNF)-{alpha} therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis Rheumatology, May 1, 2002; 41(5): 484 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A A den Broeder, L A B Joosten, T Saxne, D Heinegard, H Fenner, A M M Miltenburg, W L H Frasa, L J van Tits, W A Buurman, P L C M van Riel, et al. Long term anti-tumour necrosis factor {alpha} monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann Rheum Dis, April 1, 2002; 61(4): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Klimiuk, S. Sierakowski, R. Latosiewicz, B. Cylwik, J. Skowronski, and J. Chwiecko Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis Rheumatology, January 1, 2002; 41(1): 78 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Ronday, W. H. van der Laan, P. P. Tak, J. A. D. M. de Roos, R. A. Bank, J. M. TeKoppele, C. J. Froelich, C. E. Hack, P. C. W. Hogendoorn, F. C. Breedveld, et al. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis Rheumatology, January 1, 2001; 40(1): 55 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ribbens, B. Andre, O. Kaye, M.-J. Kaiser, V. Bonnet, J.-M. Jaspar, D. de Groote, N. Franchimont, and M. G. Malaise Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not Rheumatology, December 1, 2000; 39(12): 1357 - 1365. [Abstract] [Full Text] [PDF]
|
|